RESUMEN
The major salivary glands are the paired parotid, submandibular, and sublingual glands. Salivary gland disorders can affect the glandular tissue or its excretory system. The parotid glands are the largest and produce aqueous serous secretions that are less immunogenic. They are more susceptible to infections and neoplasms. The submandibular glands produce mucinous secretions that are high in calcium and phosphate salts through a long submandibular duct that flows against gravity. The submandibular glands are responsible for more than 80% of salivary stones. Sialadenitis can be acute or chronic and caused by bacterial, viral, and obstructive etiologies; the most common bacteria is Staphylococcus aureus. The most common viral etiologies in children are mumps (globally) and juvenile recurrent parotitis (in vaccinated populations). Sialadenosis is a chronic asymptomatic enlargement of the salivary glands due to systemic disease. Sialolithiasis causes up to 50% of salivary gland disorders. It is associated with salivary stasis and inflammation caused by dehydration, malnutrition, medications, or chronic illness. Obstruction is also caused by trauma, stenosis, and mucoceles. Neoplasms are rare and typically benign, but they warrant referral and imaging with ultrasonography, computed tomography, or magnetic resonance sialography. Most disorders are managed with conservative measures by treating the underlying etiology, optimizing predisposing factors, controlling pain, and increasing salivary flow with sialagogues, hydration, massage, warm compresses, oral hygiene, and medication adjustment. Sialendoscopy is a gland-sparing technique that can treat obstructive and nonobstructive disorders. (Am Fam Physician. 2024;109(6):550-559.
Asunto(s)
Enfermedades de las Glándulas Salivales , Humanos , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/terapia , Enfermedades de las Glándulas Salivales/etiología , Sialadenitis/diagnóstico , Sialadenitis/terapiaRESUMEN
Benign and malignant salivary gland disorders are uncommon in the pediatric population; however, these can be frequently seen in pediatric otolaryngology or oral and maxillofacial surgery practices. The astute clinician should be aware of the clinical presentation, diagnosis, and management options for common inflammatory, infectious, benign, and malignant disorders of salivary glands.
Asunto(s)
Enfermedades de las Glándulas Salivales , Neoplasias de las Glándulas Salivales , Humanos , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/terapia , Niño , Neoplasias de las Glándulas Salivales/patología , Neoplasias de las Glándulas Salivales/diagnóstico , Neoplasias de las Glándulas Salivales/cirugía , Diagnóstico Diferencial , Glándulas Salivales/patologíaRESUMEN
This paper provides an overview of the most common cause of salivary gland complaints presenting to the general dental practitioner, obstructive salivary gland disease (OSGD). It is important to be aware of the characteristic signs and symptoms to allow for appropriate management and onward referral.
Asunto(s)
Odontólogos , Enfermedades de las Glándulas Salivales , Humanos , Rol Profesional , Derivación y Consulta , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/etiología , Enfermedades de las Glándulas Salivales/terapia , Glándulas SalivalesRESUMEN
Salivary disease may present as pain or swelling in unilateral or bilateral salivary glands. Symptoms may be periprandial or recurrent and inflammatory. If a patient fails conservative treatment, they should be referred to an otolaryngologist. If there is no clear cause based on history and physical examination, sialendoscopy can be performed to directly visualize tissues, provide a diagnosis, drive treatment plans, and sometimes concurrently provide therapeutic intervention. Based on the pathology visualized on sialendoscopy, treatment options include endoscopic intervention, Botox, and gland-preserving surgical techniques, which promote healing of glandular tissue, ultimately preserving function.
Asunto(s)
Enfermedades de las Glándulas Salivales/patología , Enfermedades de las Glándulas Salivales/terapia , Diagnóstico Diferencial , Endoscopía , Humanos , Examen Físico , Atención Primaria de Salud , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/etiología , Glándulas Salivales/patologíaRESUMEN
Salivary gland diseases are rare. In the European Union (EU) a disease is considered to be rare if not more than 5 of 10,000 people are affected by it. According to estimates in Germany are about 4 million people with a rare disease. In the EU are about 30 million people with rare diseases [1]. In the present work most of the described diseases of salivary glands and of the facial nerve fall in this category. They form a very heterogeneous group whose treatment takes place mainly in specialized centers. Still, it is essential for the otolaryngologist to identify and to diagnose these diseases in order to initiate the right therapeutic steps. The work is a compilation of innate andacquired rare salivary gland disorders and of rare facial nerve disorders. The etiologies of inflammatory diseases, autoimmune disorders and tumors are taken into account. For the individual topics, the current literature, if available, was evaluated and turned into summarized facts. In this context the development of new processes, diagnostics, imaging and therapy are considered. Genetic backgrounds of salivary gland tumors and the trends in the treatment of tumorous lesions of the facial nerve are picked up. Furthermore, also rare diseases of the salivary glands in childhood are described. Some of them can occur in adults as well, but differ in frequency and symptoms. Due to the rarity of these diseases, it is recommended to tread these in centers with special expertise for it. Finally, the difficulties of initiation of studies and the problems of establishing disease registries concerning salivary gland disorders are discussed. This is very relevant because these pathologies are comparatively seldom.
Asunto(s)
Enfermedades de las Glándulas Salivales , Neoplasias de las Glándulas Salivales , Adulto , Nervio Facial , Humanos , Enfermedades Raras/terapia , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/epidemiología , Enfermedades de las Glándulas Salivales/terapia , Neoplasias de las Glándulas Salivales/diagnóstico , Neoplasias de las Glándulas Salivales/epidemiología , Neoplasias de las Glándulas Salivales/terapia , Glándulas SalivalesRESUMEN
PURPOSE: To provide evidence-based recommendations for prevention and management of salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies. METHODS: Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and ASCO convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials published between January 2009 and June 2020. The guideline also incorporated two previous systematic reviews conducted by MASCC/ISOO, which included studies published from 1990 through 2008. RESULTS: A total of 58 publications were identified: 46 addressed preventive interventions and 12 addressed therapeutic interventions. A majority of the evidence focused on the setting of radiation therapy for head and neck cancer. For the prevention of salivary gland hypofunction and/or xerostomia in patients with head and neck cancer, there is high-quality evidence for tissue-sparing radiation modalities. Evidence is weaker or insufficient for other interventions. For the management of salivary gland hypofunction and/or xerostomia, intermediate-quality evidence supports the use of topical mucosal lubricants, saliva substitutes, and agents that stimulate the salivary reflex. RECOMMENDATIONS: For patients who receive radiation therapy for head and neck cancer, tissue-sparing radiation modalities should be used when possible to reduce the risk of salivary gland hypofunction and xerostomia. Other risk-reducing interventions that may be offered during radiation therapy for head and neck cancer include bethanechol and acupuncture. For patients who develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubricants, saliva substitutes, and sugar-free lozenges or chewing gum. For patients with head and neck cancer, oral pilocarpine and oral cevimeline, acupuncture, or transcutaneous electrostimulation may be offered after radiation therapy.Additional information can be found at www.asco.org/supportive-care-guidelines.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Quimioradioterapia/efectos adversos , Neoplasias/terapia , Guías de Práctica Clínica como Asunto/normas , Enfermedades de las Glándulas Salivales/patología , Trasplante de Células Madre/efectos adversos , Xerostomía/patología , Humanos , Neoplasias/patología , Pronóstico , Enfermedades de las Glándulas Salivales/etiología , Enfermedades de las Glándulas Salivales/terapia , Sociedades Médicas , Xerostomía/etiología , Xerostomía/terapiaRESUMEN
Aging-related salivary dysfunction commonly induces the poor oral health, including decreased saliva flow and dental caries. Although the clinical significance of the salivary glands is well-known, the complex metabolic pathways contributing to the aging-dysfunction process are only beginning to be uncovered. Here, we provide a comprehensive overview of the metabolic changes in aging-mediated salivary gland dysfunction as a key aspect of oral physiology. Several metabolic neuropeptides or hormones are involved in causing or contributing to salivary gland dysfunction, including hyposalivation and age-related diseases. Thus, aging-related metabolism holds promise for early diagnosis, increased choice of therapy and the identification of new metabolic pathways that could potentially be targeted in salivary gland dysfunction.
Asunto(s)
Envejecimiento/metabolismo , Metabolismo Energético , Glándulas Salivales/metabolismo , Animales , Biomarcadores , Manejo de la Enfermedad , Susceptibilidad a Enfermedades , Hormonas/metabolismo , Humanos , Metabolómica/métodos , Saliva/metabolismo , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/etiología , Enfermedades de las Glándulas Salivales/metabolismo , Enfermedades de las Glándulas Salivales/terapia , Glándulas Salivales/patologíaRESUMEN
HIV-associated salivary gland disease refers to the pathology in head and neck lesions such as ranula, salivary gland swelling, xerostomia, and benign lymphoepithelial cysts in the parotid gland. Here, we present a unique case of the ranula patient with HIV infection treated with OK-423 sclerotherapy. Case report: The patient was a 42-year-old Japanese male with a few months history of oral floor swelling. Computed tomography (CT) showed a low-density area limited within the right floor of the mouth. Magnetic resonance imaging (MRI) revealed a distinct T2-high intensity area localized on the same location. The puncture fluid was bloody mucus, and the cytology was no malignancy. We diagnosed a simple ranula. He was, however, found to be HIV-antibody positive at the examination before treatment by chance. He was referred to the department of infectious diseases and definitively diagnosed HIV infection by western blot. We chose OK-432 sclerotherapy because of its minimally invasive and the risk of HIV infecting medical staff. Two times OK-432 injection made the lesion disappear. Conclusion: The case indicated that OK-432 sclerotherapy could be effective for ranula related to HIV.
Asunto(s)
Infecciones por VIH/complicaciones , Ránula/terapia , Enfermedades de las Glándulas Salivales/terapia , Escleroterapia , Adulto , Humanos , Inyecciones Intralesiones , Imagen por Resonancia Magnética , Masculino , Ránula/diagnóstico por imagen , Ránula/etiología , Enfermedades de las Glándulas Salivales/diagnóstico por imagen , Enfermedades de las Glándulas Salivales/etiología , Tomografía Computarizada por Rayos XRESUMEN
The treatment of salivary gland diseases represents an important segment of otorhinolaryngology. The individual otorhinolaryngologist might, however, see only a few cases per year from a large variety of salivary gland diseases. Surgical and endoscopic minimal-invasive therapy concepts play a key role. Therefore, gain of knowledge cannot only be provided by prospective clinical trials but also by meta-analyses and potentially also by registry data. Many reliable indicators are established to measure the function of a diseased salivary gland or the improvement of its function after therapy. In contrast, patient-reported outcome measures (PROMs) are not sufficiently developed. It has to be demanded that these indicators are consequently used in clinical trials. Perspectively, the same indicators could also be used for quality control for the outpatient and inpatient sector in clinical routine. The framework conditions for high-quality acquisition of knowledge are given by the otorhinolaryngology specialist medical training, the obligation of life-long continuous medical education, and certified salivary gland courses. Nevertheless, the specifications of quality standards for the treatment of patients with salivary gland diseases are not well formulated. In contrast to other disciplines also addressing salivary gland diseases, otorhinolaryngology ought to develop standards with high requirements of quality of care for salivary gland diseases.
Asunto(s)
Enfermedades de las Glándulas Salivales , Endoscopía , Humanos , Estudios Prospectivos , Calidad de Vida , Enfermedades de las Glándulas Salivales/terapia , Glándulas SalivalesRESUMEN
Permanent damage to the salivary glands and resulting hyposalivation and xerostomia have a substantial impact on patient health, quality of life, and healthcare costs. Currently, patients rely on lifelong treatments that alleviate the symptoms, but no long-term restorative solutions exist. Recent advances in adult stem cell enrichment and transplantation, bioengineering, and gene transfer have proved successful in rescuing salivary gland function in a number of animal models that reflect human diseases and that result in hyposalivation and xerostomia. By overcoming the limitations of stem cell transplants and better understanding the mechanisms of cellular plasticity in the adult salivary gland, such studies provide encouraging evidence that a regenerative strategy for patients will be available in the near future.
Asunto(s)
Regeneración/fisiología , Enfermedades de las Glándulas Salivales/terapia , Glándulas Salivales/fisiología , Animales , Humanos , Calidad de Vida , Trasplante de Células Madre/métodos , Ingeniería de Tejidos/métodosRESUMEN
The salivary glands produce saliva, which helps in mediating the oral colonization of microbes, the repair of mucosa, the remineralization of teeth, lubrication and gustation. However, certain medications, therapeutic radiation and certain autoimmune diseases can cause a reduction in the salivary flow. The aim of this report was to review and highlight the indications and techniques of salivary gland engineering to counter hyposalivation. This report concludes that in the literature, numerous strategies have been suggested and discussed pertaining to the engineering of salivary gland, however, challenges remain in terms of its production and accurate function. Dedicated efforts are required from researchers all over the world to obtain the maximum benefits from salivary gland engineering techniques.
Asunto(s)
Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Enfermedades de las Glándulas Salivales/terapia , Glándulas Salivales/citología , Ingeniería de Tejidos/métodos , Animales , HumanosRESUMEN
Abstract Introduction Diseases of the salivary glands are rare in children and adolescents, with the exception of viral-induced infections. Objective To determine the clinical course of the disease, the diagnostic procedures, the treatment and the outcome of all children and adolescents affected with salivary gland diseases at our clinic over a period of 15 years. Methods A retrospective chart review including a long-term follow-up was conducted among 146 children and adolescents treated for salivary gland disorders from 2002 to 2016. Results Diagnosing acute sialadenitis was easily managed by all doctors regardless of their specialty. The diagnosis of sialolithiasis was rapidly made only by otorhinolar- yngologists, whereas diagnosing juvenile recurrent parotitis imposed difficulties to doctors of all specialties - resulting in a significant delay between the first occurrence of symptoms and the correct diagnosis. The severity-adjusted treatment yielded improve- ments in all cases, and a full recovery of 75% of the cases of sialolithiasis, 73% of the cases of juvenile recurrent parotitis, and 100% of the cases of acute sialadenitis. Conclusions Due to their low prevalence and the lack of pathognomonic symptoms, salivary gland diseases in children and adolescents are often misdiagnosed, resulting in an unneces- sarily long period of suffering despite a favorable outcome following the correct treatment.
Asunto(s)
Humanos , Masculino , Femenino , Lactante , Preescolar , Niño , Adolescente , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/patología , Enfermedades de las Glándulas Salivales/terapia , Enfermedades de las Glándulas Salivales/epidemiología , Parotiditis/epidemiología , Sialadenitis/epidemiología , Espectroscopía de Resonancia Magnética , Cálculos de las Glándulas Salivales/epidemiología , Tomografía Computarizada por Rayos X , Registros Médicos , Incidencia , Prevalencia , Estudios Retrospectivos , Estudios Longitudinales , Ultrasonografía , Biopsia con Aguja Fina , AlemaniaRESUMEN
Las glándulas salivales humanas pueden ser gravemente lesionadas por la radioterapia utilizada contra neoplasias de cabeza y cuello, produciendo hiposialia y xerostomía, las cuales afectan la salud oral y sistémica, mermando la calidad de vida de la persona. Los tratamientos convencionales actuales están diseñados para disminuir los síntomas, sin actuar sobre los cambios fisiopatológicos que se dan a nivel glandular. Esta revisión intenta analizar aquellas terapias preventivas y/o curativas que están desarrollándose en el campo biomolecular y que tienen un futuro prometedor por sus características innovadoras: terapia génica, terapia con células madre y terapia con factores de crecimiento. Se evidencia un aporte adicional de la nanotecnología, la cual está mejorando las vías de aplicación de los tratamientos.
Human salivary glands can be seriously injured by the radiotherapy used against head and neck neoplasms, producing hyposialia and xerostomy, which affect oral and systemic health, diminishing the person's quality of life. Current conventional treatments are designed to reduce symptoms, without acting on the pathophysiological changes that occur at the glandular level. This review attempts to analyze those preventive and /or curative therapies that are developing in the biomolecular field and that have a promising future due to their innovative features: Gene therapy, stem cell therapy and growth factor therapy. An additional contribution of nanotechnology is evident, which is improving the routes of treatment application.
Asunto(s)
Humanos , Radioterapia/efectos adversos , Enfermedades de las Glándulas Salivales/prevención & control , Células Madre/fisiología , Terapia Genética/métodos , Péptidos y Proteínas de Señalización Intercelular/uso terapéutico , Traumatismos por Radiación/prevención & control , Protectores contra Radiación/uso terapéutico , Enfermedades de las Glándulas Salivales/terapia , Glándulas Salivales/efectos de la radiación , Xerostomía/prevención & control , NanotecnologíaRESUMEN
Initial signs and symptoms offer the best guide to next steps in assessment, testing, and treatment, plus any needed referral or multidisciplinary care.
Asunto(s)
Enfermedades de las Glándulas Salivales/diagnóstico , Diagnóstico Diferencial , Humanos , Derivación y Consulta , Enfermedades de las Glándulas Salivales/complicaciones , Enfermedades de las Glándulas Salivales/terapia , Evaluación de SíntomasRESUMEN
BACKGROUND: The most manifest long-term consequences of radiation therapy in the head and neck cancer patient are salivary gland hypofunction and a sensation of oral dryness (xerostomia). METHODS: This critical review addresses the consequences of radiation injury to salivary gland tissue, the clinical management of salivary gland hypofunction and xerostomia, and current and potential strategies to prevent or reduce radiation injury to salivary gland tissue or restore the function of radiation-injured salivary gland tissue. RESULTS: Salivary gland hypofunction and xerostomia have severe implications for oral functioning, maintenance of oral and general health, and quality of life. Significant progress has been made to spare salivary gland function chiefly due to advances in radiation techniques. Other strategies have also been developed, e.g., radioprotectors, identification and preservation/expansion of salivary stem cells by stimulation with cholinergic muscarinic agonists, and application of new lubricating or stimulatory agents, surgical transfer of submandibular glands, and acupuncture. CONCLUSION: Many advances to manage salivary gland hypofunction and xerostomia induced by radiation therapy still only offer partial protection since they are often of short duration, lack the protective effects of saliva, or potentially have significant adverse effects. Intensity-modulated radiation therapy (IMRT), and its next step, proton therapy, have the greatest potential as a management strategy for permanently preserving salivary gland function in head and neck cancer patients.Presently, gene transfer to supplement fluid formation and stem cell transfer to increase the regenerative potential in radiation-damaged salivary glands are promising approaches for regaining function and/or regeneration of radiation-damaged salivary gland tissue.
Asunto(s)
Neoplasias de Cabeza y Cuello/complicaciones , Radioterapia/efectos adversos , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/etiología , Xerostomía/diagnóstico , Xerostomía/etiología , Manejo de la Enfermedad , Susceptibilidad a Enfermedades , Neoplasias de Cabeza y Cuello/terapia , Humanos , Radioterapia/métodos , Investigación , Enfermedades de las Glándulas Salivales/terapia , Xerostomía/terapiaRESUMEN
In this review, the various salivary gland diseases in children are presented in a systematic manner, and their diagnosis and treatment are discussed. This will hopefully improve the knowledge about these diseases and lead to earlier diagnosis and start of treatment, if indicated. Salivary gland diseases in children are relatively rare and can pose diagnostic difficulties. It is important to differentiate between the various aetiologies and to determine the correct diagnosis and begin proper treatment.
Asunto(s)
Enfermedades de las Glándulas Salivales , Niño , Humanos , Enfermedades de las Glándulas Salivales/diagnóstico , Enfermedades de las Glándulas Salivales/terapiaRESUMEN
OBJECTIVE: This systematic review evaluated the efficacy of immunobiologics for the management of oral disease in Sjögren's syndrome (SS). MATERIALS AND METHODS: MEDLINE® , Embase, Scopus, and the Cochrane Library were searched for evidence on the use of immunobiologics for management of glandular disease in SS. Primary outcomes were xerostomia and salivary gland dysfunction, assessed via visual analogue scales, disease-specific scales for SS, measurement of salivary flow, ultrasound data, and quality of life measures. RESULTS: Seventeen studies (11 randomized controlled trials and 6 observational studies) met inclusion criteria. Rituximab showed efficacy in improving salivary gland function but not xerostomia. Abatacept showed promise in improving both xerostomia and salivary flow. Belimumab exhibited long-term improvement of salivary flow and subjective measures. The novel agent CFZ533 improved both disease activity and patient-reported indexes. CONCLUSIONS: There is strong evidence pointing to the efficacy of rituximab in the management of oral disease in SS. Future controlled trials may elucidate the efficacy of belimumab and abatacept. The new drug CFZ533 is a promising alternative for the management of SS and its salivary gland involvement. In considering these agents, the promise of efficacy must be balanced against the harmful effects associated with biologic agents.
Asunto(s)
Antirreumáticos/uso terapéutico , Factores Biológicos/uso terapéutico , Estudios Observacionales como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Rituximab/uso terapéutico , Enfermedades de las Glándulas Salivales/terapia , Glándulas Salivales/fisiopatología , Síndrome de Sjögren/tratamiento farmacológico , Xerostomía/fisiopatología , Congresos como Asunto , Humanos , Calidad de Vida , Saliva/química , Saliva/metabolismo , Enfermedades de las Glándulas Salivales/patología , Síndrome de Sjögren/fisiopatología , Escala Visual AnalógicaRESUMEN
BACKGROUND: Ranulas are salivary pseudocysts in the floor of the mouth adjacent to damaged salivary glands. Current surgical management is drainage of the ranula with removal of the offending gland. An analogous percutaneous procedure could potentially offer similar treatment efficacy in a more minimally invasive way. OBJECTIVE: To evaluate the outcomes of a cohort of patients with ranulas treated with percutaneous ranula aspiration and chemical ablation of the source salivary gland to see whether this technique could be proposed as a minimally invasive treatment alternative. MATERIALS AND METHODS: This retrospective single-center study evaluated 24 patients treated percutaneously for ranulas between January 2004 and December 2014. All patients were treated with percutaneous ranula aspiration and chemical ablation of the offending salivary gland. Treatment success and any complications were recorded. RESULTS: Complete ranula eradication was successfully accomplished in 87.5% of the patients with no complications. CONCLUSION: Initial results suggest that our technique of percutaneous aspiration of ranulas and chemical ablation of the source salivary gland is safe and effective.
Asunto(s)
Técnicas de Ablación , Etanol/uso terapéutico , Ránula/terapia , Enfermedades de las Glándulas Salivales/terapia , Ultrasonografía Intervencional , Adolescente , Niño , Preescolar , Medios de Contraste , Drenaje , Femenino , Humanos , Lactante , Masculino , Estudios Retrospectivos , Adulto JovenRESUMEN
BACKGROUND: Three-dimensional (3D) cultures recapitulate the microenvironment of tissue-resident stem cells and enable them to modulate their properties. We determined whether salivary gland-resident stem cells (SGSCs) are primed by a 3D spheroid culture prior to treating irradiation-induced salivary hypofunction using in-vitro coculture and in-vivo transplant models. METHODS: 3D spheroid-derived SGSCs (SGSCs3D) were obtained from 3D culture in microwells consisting of a nanofiber bottom and cell-repellent hydrogel walls, and were examined for salivary stem or epithelial gene/protein expression, differentiation potential, and paracrine secretory function compared with monolayer-cultured SGSCs (SGSCs2D) in vitro and in vivo. RESULTS: SGSCs3D expressed increased salivary stem cell markers (LGR5 and THY1) and pluripotency markers (POU5F1 and NANOG) compared with SGSCs2D. Also, SGSCs3D exhibited enhanced potential to differentiate into salivary epithelial cells upon differentiation induction and increased paracrine secretion as compared to SGSCs2D. Wnt signaling was activated by 3D spheroid formation in the microwells and suppression of the Wnt/ß-catenin pathway led to reduced stemness of SGSCs3D. Enhanced radioprotective properties of SGSCs3D against radiation-induced salivary hypofunction was confirmed by an organotypic 3D coculture and in-vivo transplantation experiments. CONCLUSION: The 3D spheroid culture of SGSCs in nanofibrous microwells promotes stem cell properties via activation of Wnt signaling. This may contribute to SGSC priming prior to regenerative therapy to restore salivary hypofunction after radiotherapy.